Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ(9)-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans

AIM: Cannabinoid receptor type 1 (CB(1)) antagonists have been developed for the treatment of obesity and associated risk factors. Surinabant is a high affinity CB(1) antagonist in vitro. The aim of this study was to assess the magnitude of inhibition by surinabant of CNS effects and heart rate indu...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Klumpers, Linda E, Roy, Christine, Ferron, Geraldine, Turpault, Sandrine, Poitiers, Franck, Pinquier, Jean-Louis, van Hasselt, Johan G C, Zuurman, Lineke, Erwich, Frank A S, van Gerven, Joop M A
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Blackwell Science Inc 2013
विषय:
Clinical Trials
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3703229/
https://ncbi.nlm.nih.gov/pubmed/23278647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12071
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन